Review
Biochemistry & Molecular Biology
Longfei Deng, Xuan Zhai, Ping Liang, Hongjuan Cui
Summary: TRAIL holds therapeutic potential in cancer treatment, but many cancers, including GBM, exhibit resistance. Recent studies have identified new mechanisms in regulating TRAIL-induced apoptosis in GBM and effective combinatorial strategies. The TRAIL/TRAIL death receptor axis may have future clinical applications for GBM treatment.
Article
Biochemistry & Molecular Biology
Neil Kuehnle, Scout Mask Osborne, Ziyan Liang, Mark Manzano, Eva Gottwein
Summary: KSHV infection causes PEL. Human or viral cFLIP and MC159L can effectively rescue the loss of endogenous cFLIP activity in PEL cells. However, KSHV vFLIP is unable to fully rescue the loss of endogenous cFLIP and is functionally distinct.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Pharmacology & Pharmacy
Weiqiang Zhou, Han Han, Junnan Xu, Tao Sun, Xiuyan Feng
Summary: The combination of Chidamide and TRAIL has been shown to effectively induce breast cancer cell death while reducing the concentration of Chidamide. Additionally, the combination treatment also inhibits breast cancer tumor growth and is correlated with the expression of related apoptosis and autophagy factors.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Biochemistry & Molecular Biology
Christian Holmgren, Ellen Sunstrom Thornberg, Victoria Granqvist, Christer Larsson
Summary: This study reveals the molecular mechanisms of apoptosis induction by the combination therapy of Smac mimetics and TNF-related apoptosis-inducing ligand (TRAIL) in breast cancer cells. The results demonstrate that the combination treatment bypasses the c-FLIP-mediated inhibition of caspase activation through the formation of a complex including RIP1 and caspase-8.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Oncology
Fenghao Geng, Fen Yang, Fang Liu, Jianhui Zhao, Rui Zhang, Shijie Hu, Jie Zhang, Xiao Zhang
Summary: MiR-137 increases the sensitivity of GBM cells to TRAIL-induced apoptosis by targeting XIAP. Combined application of miR-137 and TRAIL effectively suppresses tumor growth in a xenograft model.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xinhuan Wang, Ke Liu, Huimin Gong, Dezhi Li, Wenfeng Chu, Dan Zhao, Xiaofeng Wang, Dongyang Xu
Summary: Quisinostat significantly inhibits the viability, growth, and migration of tongue squamous cell carcinoma cells, and induces apoptosis, pyroptosis, and ferroptosis. It also shows a significant inhibitory effect on tumor tissue growth in animal experiments. This study suggests that quisinostat may be a potential drug for the treatment of tongue squamous cell carcinoma.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jing Liu, Li Zhang, Ling Guo, Yan Zeng, Qulian Guo, Chunmei Yang, Jian Shu, Wenjun Liu, Lu Yang
Summary: Compound 11, a hybrid Celecoxib-HDAC inhibitor, exhibited significant induction of cell death and inhibition of cell growth in NALM6 cells, making it a potential chemotherapeutic agent for ALL.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Hae-Ahm Lee, Ki-Back Chu, Eun-Kyung Moon, Fu-Shi Quan
Summary: This study revealed that HDACi suppresses the expression of GPX8, sensitizing HCC cells to ER stress and oxidative stress, leading to apoptosis.
Article
Oncology
Xiangjun Tang, Hao Peng, Pengfei Xu, Li Zhang, Rui Fu, Hanjun Tu, Xingrong Guo, Kuanming Huang, Junti Lu, Hu Chen, Zhiqiang Dong, Longjun Dai, Jie Luo, Qianxue Chen
Summary: This study investigated the effectiveness of an mRNA-based therapeutic strategy using PTEN-mRNA and TRAIL-mRNA in tumor cells derived from PTEN-deletion patients. The combination treatment of PTEN-mRNA and TRAIL-mRNA showed significant tumor growth suppression and the JNK pathway may be involved. This study provides a basis for developing an mRNA-based therapeutic strategy for GBM.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Chemistry, Multidisciplinary
Hyeonwoo Je, Gi-Hoon Nam, Gi Beom Kim, Wonjun Kim, Soo Rin Kim, In-San Kim, Eun Jung Lee
Summary: TRAIL shows promising anti-tumor activity, but faces challenges such as resistance and delivery issues. A nanocage has been developed to efficiently deliver TRAIL and a re-sensitizing drug (DOX) to overcome TRAIL-resistant tumors, demonstrating potential as an effective antitumor agent.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Ramy Ashry, Al-Hassan M. Mustafa, Kristin Hausmann, Michael Linnebacher, Susanne Strand, Wolfgang Sippl, Matthias Wirth, Oliver H. Kraemer
Summary: Tumors in the pancreas and colon are still a clinical challenge. Different gene expression profiles between cancer cells and normal cells can be targeted by drugs that modulate protein acetylation. KH16 is a novel compound that induces hyperacetylation, leading to cell death in tumor cells while sparing normal cells. It shows superior efficacy compared to clinically established drugs. Further studies can focus on KH16 and similar compounds for cancer therapy.
Article
Genetics & Heredity
Kui Su, Qian Yuan, Huan Hou, Changhong Ke, Chaohong Huang, Shuyi Li, Jianwu Sun, Xin Yuan, Yue Lin, Yiqing Chen, Huijuan Xin, Xiaoping Liang, Zhiyun Du, Zhengqiang Yuan
Summary: This study revealed that AZD5582 enhances TRAIL sensitivity by suppressing anti-apoptotic factors, providing a potential novel therapy for HCC treatment.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2022)
Review
Physiology
Laurel A. Grisanti
Summary: Cardiovascular disease is a leading cause of death globally. Cardiomyocyte death, which occurs in heart damage and stress, contributes to cardiac dysfunction and further damages the heart. Apoptosis, a regulated form of cell death, can occur through intrinsic or extrinsic pathways. The poorly characterized TNF-related ligand TRAIL and its receptors have been found to play a role in cardiac pathology. This article aims to provide an overview of the current understanding of TRAIL and its receptors in normal and pathological conditions in the heart.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Oncology
Liqin Wang, Haojie Jin, Fleur Jochems, Siying Wang, Cor Lieftink, Isabel Mora Martinez, Giulia De Conti, Finn Edwards, Rodrigo Leite de Oliveira, Arnout Schepers, Yangyang Zhou, Jiaojiao Zheng, Wei Wu, Xingling Zheng, Shengxian Yuan, Jing Ling, Kathy Jastrzebski, Matheus Dos Santos Dias, Ji-Ying Song, Patrick N. H. Celie, Hideo Yagita, Ming Yao, Weiping Zhou, Roderick L. Beijersbergen, Wenxin Qin, Rene Bernards
Summary: Senolytics are drugs that kill senescent cells, and this study identifies cFLIP as a common vulnerability of senescent cancer cells. Activation of DR5 signaling can lead to efficient killing of senescent cancer cells and non-senescent cells can be sensitized to DR5 agonist through a bystander effect mediated by secretion of cytokines. Animal models confirm the effectiveness of combining pro-senescence therapy with DR5 activation.
Article
Biochemistry & Molecular Biology
Na Liu, Tingting Luo, Jing Zhang, Li-na Han, Wen-qi Duan, Wen-xia Lu, Huiran Qiu, Yan Lin, Yong-mei Wu, Hua Zhang, Fei-fei Yang, Di Ge
Summary: The study assessed the anticancer efficacy and potential mechanisms of a novel histone deacetylase inhibitor, YF-343, in triple-negative breast cancer. YF-343 exhibited notable cytotoxicity, apoptosis promotion, cell cycle arrest, and induction of autophagy. Combination therapy of YF-343 with the autophagy inhibitor, chloroquine, showed significant suppression of breast tumor progression.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Felix Seyfried, Felix Uli Stirnweiss, Alexandra Niedermayer, Stefanie Enzenmueller, Rebecca Louise Hoerl, Vera Muench, Stefan Koehrer, Klaus-Michael Debatin, Luder Hinrich Meyer
Summary: Targeting BCL-2 in B-cell malignancies, including precursor B-cell ALL, is a promising treatment strategy. However, the redundancy of anti-apoptotic BCL-2 family proteins may limit the efficacy of single targeting. Our study reveals the mutual substitution of BCL-XL and MCL-1 in leukemia cells and demonstrates that co-inhibition of BCL-2 and MCL-1 or BCL-XL synergistically induces apoptosis.
Editorial Material
Pediatrics
S. Kiener, M. Honig, C. Pfeiffer, A. Janda, K. -M. Debatin
MONATSSCHRIFT KINDERHEILKUNDE
(2022)
Article
Biochemistry & Molecular Biology
Astrid K. Laut, Carmen Dorneburg, Axel Furstberger, Thomas F. E. Barth, Hans A. Kestler, Klaus-Michael Debatin, Christian Beltinger
Summary: CHD5, a tumor suppressor located at 1p36, is frequently lost or silenced in aggressive neuroblastoma and many adult cancers. Low expression of CHD5 is associated with stage 4 neuroblastoma and its forced expression inhibits key aspects of the metastatic cascade in vitro. Overexpression of CHD5 leads to reduced metastasis-related genes and gene sets, while known metastasis-suppressing genes are upregulated. Additionally, knockdown of PLCL1 and p53 reverses CHD5-induced inhibition of invasion and migration in vitro.
Article
Multidisciplinary Sciences
Hanna Renk, Alex Dulovic, Alina Seidel, Matthias Becker, Dorit Fabricius, Maria Zernickel, Daniel Junker, Ruediger Gross, Janis Mueller, Alexander Hilger, Sebastian F. N. Bode, Linus Fritsch, Pauline Frieh, Anneke Haddad, Tessa Goerne, Jonathan Remppis, Tina Ganzemueller, Andrea Dietz, Daniela Huzly, Hartmut Hengel, Klaus Kaier, Susanne Weber, Eva-Maria Jacobsen, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Maximilian Stich, Burkhard Toenshoff, Georg F. Hoffmann, Barbara Mueller, Carolin Ludwig, Bernd Jahrsdoerfer, Hubert Schrezenmeier, Andreas Peter, Sebastian Hoerber, Thomas Iftner, Jan Muench, Thomas Stamminger, Hans-Juergen Gross, Martin Wolkewitz, Corinna Engel, Weimin Liu, Marta Rizzi, Beatrice H. Hahn, Philipp Henneke, Axel R. Franz, Klaus-Michael Debatin, Nicole Schneiderhan-Marra, Ales Janda, Roland Elling
Summary: This study compares the humoral immune response in children and adults following SARS-CoV-2 infection and finds that children are more likely to have asymptomatic infections and higher levels of specific antibodies that persist for a longer time. Symptomatic and asymptomatic infections induce similar humoral responses across all age groups.
NATURE COMMUNICATIONS
(2022)
Article
Chemistry, Multidisciplinary
Pengfei Xu, Mike-Andrew Westhoff, Amina Hadzalic, Klaus-Michael Debatin, Lukasz Winiarski, Jozef Oleksyszyn, Christian Rainer Wirtz, Uwe Knippschild, Timo Burster
Summary: Glioblastoma, the most aggressive tumor of the central nervous system, is difficult to treat due to invasion, chemoresistance, and recurrence. Recent research discovered that diisothiocyanate-derived mercapturic acids from Cruciferae family plants can decrease glioblastoma cell viability. When combined with certain drugs, this combination therapy has an additive or even synergistic effect in restricting cell growth. This strategy holds promise for inhibiting glioblastoma cell growth as a potential therapeutic intervention.
Article
Immunology
Monika Kustermann, Prasad Dasari, Ingrid Knape, Emma Keltsch, Jianing Liu, Silvia Pfluger, Wolfram Osen, Karlheinz Holzmann, Markus Huber-Lang, Klaus-Michael Debatin, Gudrun Strauss
Summary: Immune reactions after trauma lead to an imbalanced immunohomeostasis and immunosuppression, increasing susceptibility to secondary infections. The immunomodulatory capacity of myeloid-derived suppressor cells (MDSCs) after trauma is not well-defined. However, studies have shown that therapeutic MDSC treatment can improve post-traumatic T-cell functions and enhance the ability to respond to secondary antigen challenges.
JOURNAL OF INNATE IMMUNITY
(2023)
Review
Biochemistry & Molecular Biology
Ilio Vitale, Federico Pietrocola, Emma Guilbaud, Stuart A. Aaronson, John M. Abrams, Dieter Adam, Massimiliano Agostini, Patrizia Agostinis, Emad S. Alnemri, Lucia Altucci, Ivano Amelio, David W. Andrews, Rami Aqeilan, Eli Arama, Eric H. Baehrecke, Siddharth Balachandran, Daniele Bano, Nickolai A. Barlev, Jiri Bartek, Nicolas G. Bazan, Christoph Becker, Francesca Bernassola, Mathieu J. M. Bertrand, Marco E. Bianchi, Mikhail V. Blagosklonny, J. Magarian Blander, Giovanni Blandino, Klas Blomgren, Christoph Borner, Carl D. Bortner, Pierluigi Bove, Patricia Boya, Catherine Brenner, Petr Broz, Thomas Brunner, Rune Busk Damgaard, George A. Calin, Michelangelo Campanella, Eleonora Candi, Michele Carbone, Didac Carmona-Gutierrez, Francesco Cecconi, Francis K-M Chan, Guo-Qiang Chen, Quan Chen, Youhai H. Chen, Emily H. Cheng, Jerry E. Chipuk, John A. Cidlowski, Aaron Ciechanover, Gennaro Ciliberto, Marcus Conrad, Juan R. Cubillos-Ruiz, Peter E. Czabotar, Vincenzo D'Angiolella, Mads Daugaard, Ted M. Dawson, Valina L. Dawson, Ruggero De Maria, Bart De Strooper, Klaus-Michael Debatin, Ralph J. Deberardinis, Alexei Degterev, Giannino Del Sal, Mohanish Deshmukh, Francesco Di Virgilio, Marc Diederich, Scott J. Dixon, Brian D. Dynlacht, Wafik S. El-Deiry, John W. Elrod, Kurt Engeland, Gian Maria Fimia, Claudia Galassi, Carlo Ganini, Ana J. Garcia-Saez, Abhishek D. Garg, Carmen Garrido, Evripidis Gavathiotis, Motti Gerlic, Sourav Ghosh, Douglas R. Green, Lloyd A. Greene, Hinrich Gronemeyer, Georg Haecker, Gyorgy Hajnoczky, J. Marie Hardwick, Ygal Haupt, Sudan He, David M. Heery, Michael O. Hengartner, Claudio Hetz, David A. Hildeman, Hidenori Ichijo, Satoshi Inoue, Marja Jaeaettelae, Ana Janic, Bertrand Joseph, Philipp J. Jost, Thirumala-Devi Kanneganti, Michael Karin, Hamid Kashkar, Thomas Kaufmann, Gemma L. Kelly, Oliver Kepp, Adi Kimchi, Richard N. Kitsis, Daniel J. Klionsky, Ruth Kluck, Dmitri Krysko, Dagmar Kulms, Sharad Kumar, Sergio Lavandero, Inna N. Lavrik, John J. Lemasters, Gianmaria Liccardi, Andreas Linkermann, Stuart A. Lipton, Richard A. Lockshin, Carlos Lopez-Otin, Tom Luedde, Marion MacFarlane, Frank Madeo, Walter Malorni, Gwenola Manic, Roberto Mantovani, Saverio Marchi, Jean-Christophe Marine, Seamus J. Martin, Jean-Claude Martinou, Pier G. Mastroberardino, Jan Paul Medema, Patrick Mehlen, Pascal Meier, Gerry Melino, Sonia Melino, Edward A. Miao, Ute M. Moll, Cristina Munoz-Pinedo, Daniel J. Murphy, Maria Victoria Niklison-Chirou, Flavia Novelli, Gabriel Nunez, Andrew Oberst, Dimitry Ofengeim, Joseph T. Opferman, Moshe Oren, Michele Pagano, Theocharis Panaretakis, Manolis Pasparakis, Josef M. Penninger, Francesca Pentimalli, David M. Pereira, Shazib Pervaiz, Marcus E. Peter, Paolo Pinton, Giovanni Porta, Jochen H. M. Prehn, Hamsa Puthalakath, Gabriel A. Rabinovich, Krishnaraj Rajalingam, Kodi S. Ravichandran, Markus Rehm, Jean-Ehrland Ricci, Rosario Rizzuto, Nirmal Robinson, Cecilia M. P. Rodrigues, Barak Rotblat, Carla Rothlin, David C. Rubinsztein, Thomas Rudel, Alessandro Rufini, Kevin M. Ryan, Kristopher A. Sarosiek, Akira Sawa, Emre Sayan, Kate Schroder, Luca Scorrano, Federico Sesti, Feng Shao, Yufang Shi, Giuseppe S. Sica, John Silke, Hans-Uwe Simon, Antonella Sistigu, Anastasis Stephanou, Brent R. Stockwell, Flavie Strapazzon, Andreas Strasser, Liming Sun, Erwei Sun, Qiang Sun, Gyorgy Szabadkai, Stephen W. G. Tait, Daolin Tang, Nektarios Tavernarakis, Carol M. Troy, Boris Turk, Nicoletta Urbano, Peter Vandenabeele, Tom Vanden Berghe, Matthew G. Vander Heiden, Jacqueline L. Vanderluit, Alexei Verkhratsky, Andreas Villunger, Silvia von Karstedt, Anne K. Voss, Karen H. Vousden, Domagoj Vucic, Daniela Vuri, Erwin F. Wagner, Henning Walczak, David Wallach, Ruoning Wang, Ying Wang, Achim Weber, Will Wood, Takahiro Yamazaki, Huang-Tian Yang, Zahra Zakeri, Joanna E. Zawacka-Pankau, Lin Zhang, Haibing Zhang, Boris Zhivotovsky, Wenzhao Zhou, Mauro Piacentini, Guido Kroemer, Lorenzo Galluzzi
Summary: Apoptosis is a regulated cell death process involving caspase family proteases. Inhibiting or delaying apoptosis experimentally through pharmacological and genetic strategies has demonstrated its importance in embryonic development, tissue homeostasis, and the pathogenesis of various human disorders. Defects in apoptotic cell death machinery impair development and promote oncogenesis, while inappropriate activation of apoptosis contributes to cell loss and tissue damage in neurological, cardiovascular, renal, hepatic, infectious, neoplastic, and inflammatory conditions.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Hematology
Amadeus T. Heinz, Friso G. J. Calkoen, Alexander Derbich, Lea Miltner, Christian Seitz, Michaela Doering, Christiane Braun, Daniel Atar, Michael Schumm, Florian Heubach, Anne- Marie Arendt, Ansgar Schulz, Friedhelm R. Schuster, Roland Meisel, Brigitte Strahm, Juergen Finke, Beatrice Heineking, Susanne Stetter, Gerda Silling, Daniel Stachel, Bernd Gruhn, Klaus-Michael Debatin, Juergen Foell, Johannes H. Schulte, Wilhelm Woessmann, Christine Mauz-Koerholz, Johanna Tischer, Tobias Feuchtinger, Rupert Handgretinger, Peter Lang
Summary: Therapy-resistant viral reactivations after hematopoietic stem cell transplantation can be effectively reduced by adoptive cellular therapy with virus-specific T cells. In this study, the in-house production of virus-specific T cells in a closed system was successful and showed favorable safety profile and efficacy in 26 patients.
Article
Medicine, General & Internal
Jan-Bernd Funcke, Barbara Moepps, Julian Roos, Julia von Schnurbein, Kenneth Verstraete, Elke Froehlich-Reiterer, Katja Kohlsdorf, Adriana Nunziata, Stephanie Brandt, Alexandra Tsirigotaki, Ann Dansercoer, Elisabeth Suppan, Basma Haris, Klaus-Michael Debatin, Savvas N. Savvides, I. Sadaf Farooqi, Khalid Hussain, Peter Gierschik, Pamela Fischer-Posovszky, Martin Wabitsch
Summary: This article describes two novel homozygous leptin variants that caused intense hyperphagia, severe obesity, and high leptin levels in two unrelated children. These variants bind to the leptin receptor but have marginal signaling. In the presence of nonvariant leptin, they act as competitive antagonists. High-dose recombinant leptin treatment was initiated and gradually reduced, resulting in near-normal weight for both patients. Antidrug antibodies developed in the patients, but did not appear to affect efficacy. No severe adverse events were observed.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Pediatrics
Alina Seidel, Eva-Maria Jacobsen, Dorit Fabricius, Magdalena Class, Maria Zernickel, Carmen Blum, Carina Conzelmann, Tatjana Weil, Ruediger Gross, Sebastian F. N. Bode, Hanna Renk, Roland Elling, Maximillian Stich, Frank Kirchhoff, Klaus-Michael Debatin, Jan Muench, Ales Janda
Summary: This study investigated the serum neutralization capacity and T cell memory responses of 36 seropositive adults and 34 children approximately one year after infection with the ancestral Wuhan strain of SARS-CoV-2. The results showed that a high percentage of both adults and children retained neutralizing activity against the SARS-CoV-2 Wuhan strain, although the neutralization effect against the Omicron BA.1 variant was lower. Additionally, specific T cell memory responses against the Wuhan strain and the BA.1 variant were detected in both adults and children.
FRONTIERS IN PEDIATRICS
(2023)
Correction
Oncology
N. Gassler, C. Zhang, T. Wenger, P. A. Schnabel, H. Dienemann, K-M Debatin, J. Mattern, I. Herr
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Vladimir G. Magalhaes, Soeren Lukassen, Maike Drechsler, Jennifer Loske, Sandy S. Burkart, Sandra Wuest, Eva-Maria Jacobsen, Jobst Roehmel, Marcus A. Mall, Klaus-Michael Debatin, Roland Eils, Stella Autenrieth, Ales Janda, Irina Lehmann, Marco Binder
Summary: Children have a stronger innate immune response and enhanced cytokine-mediated interactions with epithelial cells, which may explain their remarkable resistance to COVID-19.
Article
Health Care Sciences & Services
Mike-Andrew Westhoff, Carsten Posovszky, Klaus-Michael Debatin
Summary: Vaccines are highly effective in saving lives, but unfortunately they are often met with more controversy than their safety profile justifies. The anti-vaccine movement has evolved through three generations, with the current generation being closely associated with the broader anti-COVID movement and promoting individualism over community health. It is crucial to provide better science education to the young and the general public to improve overall science literacy, and strategies to achieve this are suggested.
INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING
(2023)
Article
Immunology
Victor G. Lui, Manfred Hoenig, Berenice Cabrera-Martinez, Ryan M. Baxter, Josselyn E. Garcia-Perez, Olivia Bailey, Atanu Acharya, Karl Lundquist, Jesusa Capera, Paul Matusewicz, Frederike A. Hartl, Marco D'Abramo, Josephine Alba, Eva-Maria Jacobsen, Doris Niewolik, Myriam Lorenz, Ulrich Pannicke, Ansgar S. Schulz, Klaus-Michael Debatin, Wolfgang W. Schamel, Susana Minguet, James C. Gumbart, Michael L. Dustin, John C. Cambier, Klaus Schwarz, Elena W. Y. Hsieh
Summary: A novel LCK variant, P440S, leads to T cell dysfunction, causing recurrent infections, failure to thrive, and intestinal inflammation in infants.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Lara Rieh, Medhanie Mulaw, Katharina Kneer, Meinhard Beer, Ambros Beer, Thomas F. Bart, Vladimir Benes, Johannes Schulte, Matthias Fischer, Klaus-Michael Debatin, Christian Beltinger
Summary: In this study, tumor-associated mt and nuclear circulating variants were detected in a minority of NB patients, but the number and allelic frequency of the circulating variants did not reflect the clinical course of the tumors.